ADVENT at EAACI PAAM 2025

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.

Leonard Bacharier +2 more

Past event

24October2025

Location

Palma de Mallorca Spain

Symposium Details

October 24

Trajectories of Childhood Disease: How Type 2 Inflammation Shapes a Lifetime

Join experts Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium exploring the cumulative burden and long-term clinical consequences of uncontrolled type 2 inflammation across pediatric diseases.

Agenda

Welcome and Introductions

Len Bacharier

Unraveling the Pathophysiology Underlying Pediatric Type 2 Inflammatory Diseases

André Moreira

One Pathway, Many Problems: Type 2 Inflammation in Pediatric AD, Asthma, and EoE

Antonella Cianferoni

From Onset to Burden: Uncovering Disease Trajectories in Children With Type 2 Inflammation

Len Bacharier

Audience Q&A

All Faculty

Description

Location

Palma de Mallorca Spain

Speakers

Allergy/Immunology

Leonard Bacharier

Janie Robinson and John Moore Lee Chair of Pediatrics and Director of Center for Pediatric Asthma Research | Vanderbilt University, Tennessee, United States

Allergy/Immunology

MD, PhD

Antonella Cianferoni

Associate Professor in Pediatrics | Perelman School of Medicine, University of Pennsylvania; Medical Director of the Food Allergy Immunotherapy Program | Children’s Hospital of Philadelphia, Pennsylvania, United States

Allergy/Immunology

MD, PhD

André Moreira

André Moreira, MD, PhD, is director of immunoallergology services, executive member of the directive board, and director of the medical residence training program at the University Hospital of São João in Porto, Portugal. He is also full professor in the faculty of medicine and assistant professor of immunology in the faculty of nutrition and food sciences at the hospital’s affiliated university, the University of Porto.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region